HTG Announces Appointments of John Wineman as Vice President New Business Development–Western Region and Thomas Vasicek, Ph.D. as Vice President Clinical Programs and Product Innovation

TUCSON, Ariz. – HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced the appointments of John Wineman as Vice President New Business Development, Western Region and Thomas Vasicek, Ph.D., as Vice President Clinical Programs and Product Innovation.

Mr. Wineman will be responsible for commercial sales and new business growth for the western region of North America and Asia. “John has a tremendous background in Life Science Research and Diagnostics markets as well as a successful track record in business development, sales and marketing roles,” said BJ Kerns, Senior Vice President of HTG. “At HTG, he will play a key role in accelerating our growth and building new business relationships.”

Prior to joining HTG Mr. Wineman served as Director of Business Development for the FEI company’s Life Science Market Division. Previously, he served as Director of Strategic Marketing and Director of Corporate Development for Roche Diagnostics Group, Ventana Medical Systems Division. Mr. Wineman also held a business development role at LifeSpan Biosciences and sales management roles at Becton Dickenson and Bio-Rad Laboratories. He holds an MBA from San Diego State University and a BS in Biology from Oregon State University.

Dr. Vasicek will be responsible for leading HTG’s clinical programs, working as scientific lead with key pharma and academic collaborations and contracts as well as establishing the company’s new assay innovation roadmap. “Tom has made major contributions to medical science throughout his career; his background and experience will help propel HTG’s entrance into the molecular diagnostics market,” said TJ Johnson, HTG’s CEO. “As head of our clinical programs and diagnostic innovations, Tom will play a pivotal role in advancing HTG’s technology into new markets and applications.”

Prior to joining HTG Dr. Vasicek served as Senior Director Medical Innovation for Ventana Medical Systems, a member of the Roche Group, where he led new assay development for oncology prognostics and therapy guidance. Previously, he served as Senior Director, Bioscience Technology Development at Medtronic, Inc. Dr. Vasicek also served as Vice President, Business Development for Solexa, Inc. / Lynx Therapeutics; CSO for LabSeek Scientific Collaboration; Director, Commercial Technology for Corning Advanced Life Science Products; Senior Scientist in Target Discovery for Millennium Pharmaceuticals; and a visiting scientist at the Whitehead Institute. Dr. Vasicek was a Postdoctoral Research Fellow at Princeton University. He received his Ph.D. in Genetics from Harvard University and a B.S. in Chemistry from the Massachusetts Institute of Technology.

“I am extremely excited to add two new members to the HTG leadership team in John Wineman and Tom Vasicek,” added TJ Johnson. “These appointments validate the progress HTG has made as a personalized healthcare company and provide us the executive bandwidth to accelerate our growth into molecular diagnostics.”

About HTG

Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at https://www.htgenomics.com